Related Experiment Video

Updated: Jun 21, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth

Dan Zhu1, Jennifer Hensel, Robert Hilgraf

  • 1Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA. dzhu@celgene.com

Molecular and Cellular Biochemistry
|July 25, 2009
PubMed

Insights

New research validates protein kinase CK2 (CK2) as a cancer growth driver. Novel inhibitors targeting CK2 significantly blocked cancer cell proliferation, offering potential new cancer therapies.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Protein kinase CK2 (CK2) is a vital serine/threonine kinase regulating cell growth, survival, and differentiation.
  • Aberrant CK2 activity is frequently observed in various human cancers, implicating it in neoplastic progression.

Purpose of the Study:

  • To further validate the role of CK2 in cancer cell proliferation using RNA interference.
  • To identify novel small molecules that inhibit CK2 activity and demonstrate their anti-cancer effects.

Main Methods:

  • Utilized siRNA to investigate CK2's role in cancer cell growth.
  • Screened a large compound library (>200,000 molecules) to identify CK2 inhibitors.
  • Determined the binding mode of a lead compound with maize CK2.
  • Assessed cellular activity by measuring inhibition of PTEN Ser370 phosphorylation in HCT116 cells.

Main Results:

  • Identified multiple compounds inhibiting CK2 with IC50 values below 1 microM.
  • Demonstrated cellular efficacy of identified inhibitors by blocking PTEN Ser370 phosphorylation.
  • Showed significant inhibition of cancer cell line growth by the novel CK2 inhibitors, with IC50 values as low as 300 nM.

Conclusions:

  • The study confirms CK2's critical role in promoting cancer cell growth.
  • Novel small molecule inhibitors of CK2 have been identified with potent anti-proliferative activity against various cancer cell lines.
  • These findings support the development of CK2 inhibitors as a therapeutic strategy for cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...